(Q50785408)

19 March 2018

editorial

0 references

title

HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types? (English)

1 reference

19 March 2018

author name string

Amer A Beg

series ordinal

1

1 reference

19 March 2018

Jhanelle E Gray

series ordinal

2

1 reference

19 March 2018

publication date

13 July 2016

1 reference

19 March 2018

published in

Epigenomics

1 reference

19 March 2018

volume

8

1 reference

19 March 2018

issue

8

1 reference

19 March 2018

page(s)

1015-1017

1 reference

19 March 2018

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

cites work

1 reference

https://api.crossref.org/works/10.2217%2FEPI-2016-0066

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI-2016-0066

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI-2016-0066

Big opportunities for small molecules in immuno-oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI-2016-0066

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI-2016-0066

Evolving synergistic combinations of targeted immunotherapies to combat cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI-2016-0066

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI-2016-0066

Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI-2016-0066

Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI-2016-0066

Synergistic expression of the CXCL10 gene in response to IL-1β and IFN-γ involves NF-κB, phosphorylation of STAT1 at Tyr701, and acetylation of histones H3 and H4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI-2016-0066

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI-2016-0066

Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI-2016-0066

Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI-2016-0066

An intact immune system is required for the anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI-2016-0066

New and emerging HDAC inhibitors for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI-2016-0066

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI-2016-0066

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI-2016-0066

An immune-active tumor microenvironment favors clinical response to ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FEPI-2016-0066

21 January 2018

Identifiers

DOI

10.2217/EPI-2016-0066

1 reference

19 March 2018

1 reference

19 March 2018